logo

For the Inventor, By the Inventor

Strasbourg, France

Transgene S.a.


USPTO Granted Patents = 159

% Expired Patents = 34.6



Trademarks = 2

Forward Citations = 1,270

Loading Chart...
Loading Chart...

148 inventors (with patents filed for the assignee):

goldMedal Nathalie Silvestre (18 out of 20 patents)

silverMedal Philippe Erbs (17 out of 17 patents)

bronzeMedal Majid Mehtali (16 out of 32 patents)

4.  Marie-Paule Kieny (15 out of 18 patents)

5.  Claude Sene (12 out of 12 patents)

6.  Jean-Baptiste Marchand (10 out of 13 patents)

7.  Jean-Marc Balloul (10 out of 13 patents)

8.  Michel Geist (9 out of 9 patents)

9.  Yves Cordier (8 out of 8 patents)

10.  Jean-Pierre Lecocq (8 out of 10 patents)

11.  Richard Lathe (8 out of 15 patents)

12.  Perrine Martin (7 out of 7 patents)

13.  Christine Thioudellet (7 out of 8 patents)

14.  Marina Kapfer (7 out of 7 patents)

15.  Anne Fournillier (7 out of 9 patents)


Core Competencies:
Oncolytic Virus
HBV Treatment
Mycobacterial Vaccine
Immune Checkpoint Modulators
Poxviral Vectors
Dendritic Cells
Cytosine Deaminase
Cytokines
Papillomavirus
Adenoviral Vectors
Nucleic Acid Compositions
Pharmaceutical Compositions

159 patents:

1. 12622937 - Combination of oncolytic virus with immune checkpoint modulators (2026-05-12),
2. 11779619 - Oncolytic virus for expression of immune checkpoint modulators (2023-10-10),
3. 10857226 - Composition for treating HBV infection (2020-12-08),
4. 10765731 - Fusion of heterooligomeric mycobacterial antigens (2020-09-08),
5. 10765710 - Combination of oncolytic virus with immune checkpoint modulators (2020-09-08),
6. 10662414 - Methods for treating or preventing HBV infection or HBV related diseases (2020-05-26),
7. 10555981 - Oncolytic virus for expression of immune checkpoint modulators (2020-02-11),
8. 10517943 - Stable liquid vaccinia virus formulations (2019-12-31),
9. 10357555 - Mycobacterial antigen vaccine (2019-07-23),
10. 10190105 - HBV polymerase mutants (2019-01-29),
11. 10111947 - Virus-containing formulation and use thereof (2018-10-30),
12. 10076570 - Composition for treating HBV infection (2018-09-18),
13. 9982055 - Antibody against the CSF-1R (2018-05-29),
14. 9884080 - Poxviral oncolytic vectors (2018-02-06),
15. 9687515 - Poxviral oncolytic vectors (2017-06-27),
Transgene S.a., headquartered in Strasbourg, France, is a biotechnology company specializing in the development of innovative oncolytic virus therapies for cancer treatment. The company focuses on harnessing the power of oncolytic viruses to selectively target and destroy cancer cells while stimulating the immune system. Transgene's research encompasses various advanced therapeutic areas, including HBV treatment, mycobacterial vaccines, and immune checkpoint modulators, positioning it at the forefront of cancer immunotherapy and viral vector technology.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Transgene S.a.
159 Patents

#2 in Strasbourg

#180 in France

#5,172 in the World

Strasbourg, FR
Strasbourg, France

Transgene S.a.

Forward Citations = 1,270

148 inventors:

goldMedal Nathalie Silvestre (18 out of 20 patents)

silverMedal Philippe Erbs (17 out of 17 patents)

bronzeMedal Majid Mehtali (16 out of 32 patents)

4.  Marie-Paule Kieny (15 out of 18 patents)

5.  Claude Sene (12 out of 12 patents)

Please report any incorrect information to [email protected]
Loading…